BRAF mutation is a rare but druggable driver alteration in NSCLC. It accounts for 2-3% of metastatic lung adenocarcinoma cases in Western countries, but the frequency would be lower, at 0.5-1% in East Asia regions. To better know the updated information about BRAF mutations in NSCLC, the speaker will provide an overview of the current data for BRAF-mutant NSCLC patients in this presentation. For patients with BRAF mutations, although rare, there are several treatment options. The presenter will review the currently available data for different treatments and introduce the current ESMO guidelines for BRAF mutations and advancements in BRAF-mut NSCLC (chemotherapy, targeted therapy, and immunotherapy). Additionally, to increase participants' understanding of case management for this patient population, real-life case studies will be shared in the presentation. Together, the objective of this webinar is to enhance HCPs' understanding of BRAF mutation in NSCLC and to improve participants' ability to effectively treat BRAF-mut NSCLC with knowledge of approved therapies.